Genetics in breast cancer and treatment strategy : A current scenario

  • Authors

    • Muhammad Islam Post-Graduate Program in Pharmaceutical Science, Federal University of Piaui, Teresina (PI)- 64.049-550.
    2017-08-20
    https://doi.org/10.14419/ijm.v5i2.8077
  • Breast Cancer, Present Circumstances, Medical Science.

  • This review aims to sketch the current scenario of breast cancer, which deals with the genetics, treatment strategy, drug resistance and over-comes as well as associated symptoms.

  • References

    1. [1] American Cancer Society. 2014. What rea the key statistics about breast cancer? 2014 02/04/2015. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics.
      [2] Antoniou AC, Casadei S, Heikkinen T, et al. 2014. Breast-cancer risk in families with mutations in PALB2. New England J. Med. 371:497-506. https://doi.org/10.1056/NEJMoa1400382.
      [3] Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S. 2008. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding. Clin. Cancer Res. 14(5):1325-1332. https://doi.org/10.1158/1078-0432.CCR-07-4453.
      [4] Benusiglio PR, Malka D, Rouleau E, et al. 2013. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: A multicentre study. J. Med. Genet. 50:486-489. https://doi.org/10.1136/jmedgenet-2012-101472.
      [5] Bianco S, Gevry N. 2012. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription 3(4):165-170. https://doi.org/10.4161/trns.20496.
      [6] Breast Cancer Treatment (PDQ®). NCI. 23 May 2014. Retrieved 29 June 2014.
      [7] Chen KG, Sikic BI. 2012. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18(7):1863-1869. https://doi.org/10.1158/1078-0432.CCR-11-1590.
      [8] Christobel S, Sunil J. 2009. Breast cancer (1. ed.). Oxford: Oxford University Press. p. Chapter 13. ISBN 978-0-19-955869-8.
      [9] Cole SP, et al. 1994. Pharmacological characterization of multidrug resistant MRPtransfected human tumor cells. Cancer Res. 54(22):5902-5910.
      [10] Falasca M, Linton KJ. 2012. Investigational ABC transporter inhibitors. Expert. Opin. Investig. Drugs 21(5):657-666. https://doi.org/10.1517/13543784.2012.679339.
      [11] Fougère M, Gaudineau B, Barbier J, Guaddachi F, Feugeas JP, Auboeuf D, Jauliac S. 2010. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 29(15):2292-2301. https://doi.org/10.1038/onc.2009.499.
      [12] Garber JE, Goldstein AM, Kantor AF, et al. 1991. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 51:6094-6097.
      [13] Gaudineau B, Fougère M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S. 2012. Lipocalin 2 (LCN2), the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion. J. Cell Sci. 125(19):4475-4486. https://doi.org/10.1242/jcs.099879.
      [14] Golmard L, Caux-Moncoutier V, Davy G, et al. 2013. Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer 13:484. https://doi.org/10.1186/1471-2407-13-484.
      [15] He M, Wei MJ. 2012. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin. J. Cancer 31(3):126-133. https://doi.org/10.5732/cjc.011.10315.
      [16] Hearle N, Schumacher V, Menko FH, et al. 2006. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. 12:3209-3215. https://doi.org/10.1158/1078-0432.CCR-06-0083.
      [17] Jani M, et al. 2014. Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch. Toxicol. 88(6):1205-1248. https://doi.org/10.1007/s00204-014-1224-8.
      [18] Kerr ID, Haider AJ, Gelissen IC. 2011. The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br. J. Pharmacol. 164(7):1767-1779. https://doi.org/10.1111/j.1476-5381.2010.01177.x.
      [19] Lehmann BD, et al. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7):2750-2767. https://doi.org/10.1172/JCI45014.
      [20] Leonessa F, Clarke R. 2003. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 10(1):43-73. https://doi.org/10.1677/erc.0.0100043.
      [21] Li FP, Fraumeni JF Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71:747-752. https://doi.org/10.7326/0003-4819-71-4-747.
      [22] Lim W, Olschwang S, Keller JJ, et al. 2004. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterol. 126:1788-1794. https://doi.org/10.1053/j.gastro.2004.03.014.
      [23] Loe DW, et al. 1996. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathionedependent vincristine transport. J. Biol. Chem. 271(16):9675-9682. https://doi.org/10.1074/jbc.271.16.9675.
      [24] Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E. 2014. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. Cancer Treatment Rev. 40(2014):951-959. https://doi.org/10.1016/j.ctrv.2014.05.007.
      [25] Marighetti F, et al. 2013. Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors. ChemMedChem 8(1):125-135. https://doi.org/10.1002/cmdc.201200377.
      [26] Marusyk A, Polyak K. 2010. Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta 1805(1):105. https://doi.org/10.1016/j.bbcan.2009.11.002.
      [27] Massarut S, Baldassare G, Belleti B, Reccanello S, D'Andrea S, Ezio C, Perin T, Roncadin M, Vaidya JS. 2006. Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid. J. Clin. Oncol. 24(18S):10611.
      [28] Masuda H, et al. 2013. Differential response to neoadjuvant chemotherapy among 7 triplenegative breast cancer molecular subtypes. Clin. Cancer Res. 19(19):5533-5540. https://doi.org/10.1158/1078-0432.CCR-13-0799.
      [29] Meindl A, Hellebrand H, Wiek C, et al. 2010. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42:410-414. https://doi.org/10.1038/ng.569.
      [30] Merenbakh-Lamin K, et al. 2013. D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73(23):6856-6864. https://doi.org/10.1158/0008-5472.CAN-13-1197.
      [31] Miller TW, et al. 2009. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 69(10):4192-4201. https://doi.org/10.1158/0008-5472.CAN-09-0042.
      [32] Mross K, et al. 1993. Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol. 4(1):45-50. https://doi.org/10.1093/oxfordjournals.annonc.a058356.
      [33] Nass N, Kalinski T. 2015. Tamoxifen resistance: From cell culture experiments towards novel biomarkers. Pathol. Res. Practice 211(3):189-197. https://doi.org/10.1016/j.prp.2015.01.004.
      [34] National Comprehensive Cancer Network. 2014. NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Breast and ovarian. http://www.nccn.org/professionals/physician_ gls/f_guidelines.asp. Accessed January 27, 2016.
      [35] Offit K, Pierce H, Kirchhoff T, et al. 2003. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med. Genet. 4:1. https://doi.org/10.1186/1471-2350-4-1.
      [36] Parker JS, et al. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27(8):1160-1167. https://doi.org/10.1200/JCO.2008.18.1370.
      [37] Pasche B. 2010. Cancer Genetics (Cancer Treatment and Research). Berlin: Springer. p. 19-20. ISBN 1-4419-6032-5.
      [38] Paul S, et al. 1996. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc. Natl. Acad. Sci. U S A 93(14):6929-6934. https://doi.org/10.1073/pnas.93.14.6929.
      [39] Raha P, Thomas S, Munster PN. 2011. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics 3(4):451-470. https://doi.org/10.2217/epi.11.72.
      [40] Screening. 2015. Centers for Disease Control and Prevention. Retrieved 17 November 2015.
      [41] Sotiriou C, Pusztai L. 2009. Gene-Expression Signatures in Breast Cancer. New England J. Med. 360(8):790-800. https://doi.org/10.1056/NEJMra0801289.
      [42] Tan MH, Mester JL, Ngeow J, et al. 2012. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. 18:400-407. https://doi.org/10.1158/1078-0432.CCR-11-2283.
      [43] Tang Y, et al. 2015. Fast, Stable Induction of P-Glycoprotein-mediated Drug Resistance in BT- 474 Breast Cancer Cells by Stable Transfection of ABCB1 Gene. Anticancer Res. 35(5):2531-2538.
      [44] Vtorushin SV, et al. 2014. The phenomenon of multi-drug resistance in the treatment of malignant tumors. Exp. Oncol. 36(3):144-156.
      [45] Vu T, Claret FX. 2012. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2:62. https://doi.org/10.3389/fonc.2012.00062.
      [46] Win AK, Lindor NM, Young JP, et al. 2012. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. J. Natl. Cancer Inst. 104:1363-1372. https://doi.org/10.1093/jnci/djs351.
      [47] Win AK, Young JP, Lindor NM, et al. 2012. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J. Clin. Oncol. 30:958-964. https://doi.org/10.1200/JCO.2011.39.5590.
      [48] Wind NS, Holen I. 2011. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011:967419. https://doi.org/10.4061/2011/967419.
      [49] World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.2. ISBN 92-832-0429-8.
      [50] Wu AH, Yu MC, Tseng CC, Pike MC. 2008. Epidemiology of soy exposures and breast cancer risk. British J. Cancer 98(1): 9-14. https://doi.org/10.1038/sj.bjc.6604145.
      [51] Zaman GJ, et al. 1994. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U S A 91(19):8822-8826. https://doi.org/10.1073/pnas.91.19.8822.
      [52] Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. 2013. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 346:f3706. https://doi.org/10.1136/bmj.f3706.

  • Downloads

  • How to Cite

    Islam, M. (2017). Genetics in breast cancer and treatment strategy : A current scenario. International Journal of Medicine, 5(2), 223-225. https://doi.org/10.14419/ijm.v5i2.8077